<?xml version='1.0' encoding='utf-8'?>
<document id="28913815"><sentence text="Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity."><entity charOffset="44-53" id="DDI-PubMed.28913815.s1.e0" text="Cisplatin" /><entity charOffset="73-81" id="DDI-PubMed.28913815.s1.e1" text="Mannitol" /><entity charOffset="118-127" id="DDI-PubMed.28913815.s1.e2" text="Cisplatin" /><pair ddi="false" e1="DDI-PubMed.28913815.s1.e0" e2="DDI-PubMed.28913815.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28913815.s1.e0" e2="DDI-PubMed.28913815.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28913815.s1.e0" e2="DDI-PubMed.28913815.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28913815.s1.e1" e2="DDI-PubMed.28913815.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28913815.s1.e1" e2="DDI-PubMed.28913815.s1.e2" /></sentence><sentence text="Forced diuresis, high-volume hydration with diuresis, is widely used as a prophylactic treatment against cisplatin nephrotoxicity"><entity charOffset="105-114" id="DDI-PubMed.28913815.s2.e0" text="cisplatin" /></sentence><sentence text=" However, the details of the underlying mechanisms and the optimal protocol of forced diuresis remain unclear" /><sentence text=" The present study investigated the alterations in pharmacokinetics and pharmacodynamics (nephrotoxicity) of cisplatin with forced diuresis treatment"><entity charOffset="109-118" id="DDI-PubMed.28913815.s4.e0" text="cisplatin" /></sentence><sentence text="" /><sentence text="Cisplatin (5 mg/kg) was intravenously injected to rats (5 rats/group, except for control group in pharmacodynamic study, n = 13) treated with or without forced diuresis 2-h pre- and post-hydration with 10% mannitol at different infusion rates (0"><entity charOffset="0-9" id="DDI-PubMed.28913815.s6.e0" text="Cisplatin" /><entity charOffset="206-214" id="DDI-PubMed.28913815.s6.e1" text="mannitol" /><pair ddi="false" e1="DDI-PubMed.28913815.s6.e0" e2="DDI-PubMed.28913815.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28913815.s6.e0" e2="DDI-PubMed.28913815.s6.e1" /></sentence><sentence text="3, 1" /><sentence text="0, and 3" /><sentence text="0 mL/h)" /><sentence text=" The unbound cisplatin concentrations in plasma and urine, and the platinum amount in the kidney were monitored in the pharmacokinetic studies"><entity charOffset="13-22" id="DDI-PubMed.28913815.s10.e0" text="cisplatin" /><entity charOffset="67-75" id="DDI-PubMed.28913815.s10.e1" text="platinum" /><pair ddi="false" e1="DDI-PubMed.28913815.s10.e0" e2="DDI-PubMed.28913815.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28913815.s10.e0" e2="DDI-PubMed.28913815.s10.e1" /></sentence><sentence text=" The plasma creatinine concentration was evaluated as an index of nephrotoxicity in the pharmacodynamic studies"><entity charOffset="12-22" id="DDI-PubMed.28913815.s11.e0" text="creatinine" /></sentence><sentence text="" /><sentence text="Forced diuresis treatment did not significantly alter the plasma cisplatin pharmacokinetics but dramatically decreased the urine concentration of unbound cisplatin and its accumulation into the kidneys in a dose-dependent manner, and correspondingly, nephrotoxicity was dose-dependently attenuated by forced diuresis"><entity charOffset="65-74" id="DDI-PubMed.28913815.s13.e0" text="cisplatin" /><entity charOffset="154-163" id="DDI-PubMed.28913815.s13.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.28913815.s13.e0" e2="DDI-PubMed.28913815.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28913815.s13.e0" e2="DDI-PubMed.28913815.s13.e1" /></sentence><sentence text=" The pharmacokinetic-pharmacodynamic analysis suggested that the urine cisplatin concentration has a comparable impact on the cisplatin-induced nephrotoxicity to that in plasma, probably owing to the reabsorption of cisplatin from urine, which can be attenuated by forced diuresis"><entity charOffset="71-80" id="DDI-PubMed.28913815.s14.e0" text="cisplatin" /><entity charOffset="126-135" id="DDI-PubMed.28913815.s14.e1" text="cisplatin" /><entity charOffset="216-225" id="DDI-PubMed.28913815.s14.e2" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.28913815.s14.e0" e2="DDI-PubMed.28913815.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28913815.s14.e0" e2="DDI-PubMed.28913815.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28913815.s14.e0" e2="DDI-PubMed.28913815.s14.e2" /><pair ddi="false" e1="DDI-PubMed.28913815.s14.e1" e2="DDI-PubMed.28913815.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28913815.s14.e1" e2="DDI-PubMed.28913815.s14.e2" /></sentence><sentence text="" /><sentence text="These results indicated that the nephroprotective effect of forced diuresis is a pharmacokinetic-based drug-drug interaction possibly due to the inhibition of cisplatin reabsorption from urine"><entity charOffset="159-168" id="DDI-PubMed.28913815.s16.e0" text="cisplatin" /></sentence><sentence text=" Monitoring of urine cisplatin concentration may lead to the optimization of a forced diuresis protocol with mannitol"><entity charOffset="21-30" id="DDI-PubMed.28913815.s17.e0" text="cisplatin" /><entity charOffset="109-117" id="DDI-PubMed.28913815.s17.e1" text="mannitol" /><pair ddi="false" e1="DDI-PubMed.28913815.s17.e0" e2="DDI-PubMed.28913815.s17.e0" /><pair ddi="false" e1="DDI-PubMed.28913815.s17.e0" e2="DDI-PubMed.28913815.s17.e1" /></sentence><sentence text="" /></document>